Relapse is the main cause of treatment failure after allogeneic stem cell transplant (alloSCT)
in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Injectable …

Disease relapse is the most common cause of treatment failure after allogeneic stem cell
transplantation for acute myeloid leukemia and myelodysplastic syndromes, yet treatment …

BACKGROUND: Recurrence is a major cause of treatment failure after allogeneic
transplantation for acute myelogenous leukemia (AML) and myelodysplastic syndrome …

This study investigated the efficacy and safety of azacitidine maintenance in the
posttransplant setting based on the encouraging phase 1/2 reports for azacitidine …

CC-486, the oral formulation of azacitidine (AZA), is an epigenetic modifier and DNA
methyltransferase inhibitor in clinical development for treatment of hematologic …

Disease relapse is the major causes of treatment failure after allogeneic stem cell
transplantation (SCT) in patients with acute myeloid leukemia (AML). As well as …

To expand the current knowledge about azacitidine (Aza) and donor lymphocyte infusions
(DLI) as salvage therapy for relapse after allogeneic hematopoietic stem cell transplantation …

Background Although induction chemotherapy results in remission in many older patients
with acute myeloid leukemia (AML), relapse is common and overall survival is poor …

Introduction: Many older patients (pts) with AML respond to intensive induction
chemotherapy (IC), but responses are often short-lived and overall survival (OS) is poor. The …

Abstract CC‐486 (oral azacitidine) is an epigenetic modifier in clinical development for
treatment of hematological cancers. This study of extended CC‐486 dosing included …